Staying on the pulse of the latest developments

Follow the news and developments of our breakthrough discovery and development of cellular therapies for immune-mediated diseases.

The press releases contained in this section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. Cabaletta disavows any obligation to update the information contained in such press releases after the date of their issuance. 

Cabaletta Bio Announces Presentation of Preclinical Data Showing Specific CAAR T Activity against Anti-MuSK Expressing B Cells
Read More
Cabaletta Bio Receives IND Clearance from FDA to Initiate First Clinical Trial of DSG3-CAART in Patients with Mucosal Pemphigus Vulgaris
Read More
Cabaletta Bio Expands Management Team with Appointment of Brian Stalter as General Counsel
Read More